More Deal Of The Year Nominees
Executive Summary
It's time for The IN VIVO Blog's Third Annual Deal of the Year competition. This year, awards will be presented in three categories to highlight the most interesting and creative deal making solutions of 2010.
You may also be interested in...
As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow
Pfizer Inc.’s latest pledge to academic research, a five-year $85 million agreement to fund projects at the University of California, San Francisco, isn’t just a deepening of the Big Pharma’s commitment to on-campus studies intended to bridge the so-called Valley of Death between the laboratory and the commercial sector. It’s also a sign of the increased importance of deals between pharmas and universities, which give commercial partners access to new research earlier in the development process while nudging academics toward projects with commercial relevance in mind.
Deals Of The Week: Sanofi, Teva, Ablexis; Kadmon Emerges From Stealth Mode
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
King of Pain: Pfizer's Move into Abuse Resistant Opioids and the Virtues of Massive Scale
Pfizer’s $3.3 billion acquisition of King eliminates the primary opportunity for investors to play in the abuse-resistant formulation space and renewed questions about the logic of perpetual expansion atop Big Pharma. But the realities of the abuse resistant marketplace suggest it makes a good case for scale and diversity. Is this a sign of things to come in other drug classes?